Analysts Conflicted on These Healthcare Names: Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Rani Therapeutics Holdings (RANI) and Apellis Pharmaceuticals (APLS).
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rani Therapeutics Holdings (RANI)
In a report issued on March 30, Michael Okunewitch from Maxim Group maintained a Buy rating on Rani Therapeutics Holdings, with a price target of $5.00. The company’s shares closed last Wednesday at $0.69.
According to TipRanks.com, Okunewitch has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $7.00 average price target, which is an 844.7% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
Apellis Pharmaceuticals (APLS)
In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $41.00. The company’s shares closed last Wednesday at $40.40.
According to TipRanks.com, Suvannavejh is a 5-star analyst with an average return of
Apellis Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $35.89, which is a -11.1% downside from current levels. In a report released yesterday, Needham also downgraded the stock to Hold.
Read More on RANI:
